Hims & Hers Health Inc. has announced a significant expansion, doubling its facility footprint to over one million square feet in 2025. This investment integrates advanced pharmacy capabilities, lab testing, and R&D space, enabling the company to enhance individualized care at an accessible price point. Additionally, Hims & Hers is expanding its personalized weight loss portfolio by offering compounded semaglutide pills, starting at $49 for the first month, as part of a broader suite of weight loss solutions. This innovation is designed to make treatment more accessible, especially for those seeking needle-free options, and reflects the company’s ongoing commitment to increasing choice and affordability in healthcare.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205680502) on February 05, 2026, and is solely responsible for the information contained therein.